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AbstrACt
Objectives Methotrimeprazine is commonly used for 
the management of nausea but never tested formally 
against other drugs used in this setting. The aim was to 
demonstrate superior antiemetic efficacy.
Design Double-blind, randomised, controlled trial of 
methotrimeprazine versus haloperidol.
setting 11 palliative care sites in Australia.
Participants Participants were >18 years, had cancer, an 
average nausea score of ≥3/10 and able to tolerate oral 
medications. Ineligible patients had acute nausea related 
to treatment, nausea for which a specific antiemetic 
was indicated, were about to undergo a procedure or 
had received either of the study drugs or a change in 
glucocorticoid dose within the previous 48 hours.
Interventions Based on previous studies, haloperidol 
was used as the control. Participants were randomised to 
encapsulated methotrimeprazine 6·25 mg or haloperidol 
1·5 mg one time or two times per day and assessed every 
24 hours for 72 hours.
Main outcome measures A ≥two-point reduction in 
nausea score at 72 hours from baseline. Secondary 
outcome measures were as follows: complete response 
at 72 hours (end nausea score less than 3), response 
at 24 and 48 hours, vomiting episodes, use of rescue 
antiemetics, harms and global impression of change.
results Response to treatment at 72 hours was 75% 
(44/59) in the haloperidol (H) arm and 63% (36/57) in the 
methotrimeprazine (M) arm with no difference between 
groups (intention-to-treat analysis). Complete response 
rates were 56% (H) and 51% (M). In the per protocol 
analysis, there was no difference in response rates: (85% 
(44/52) (H) and 74% (36/49) (M). Complete per protocol 
response rates were 64% (H) and 59% (M). Toxicity worse 
than baseline was minimal with a trend towards greater 
sedation in the methotrimeprazine arm.
Conclusion This study did not demonstrate any difference 
in response rate between methotrimeprazine and 
haloperidol in the control of nausea.
trial registration number ACTRN 12615000177550.
IntrODuCtIOn
Many people with cancer experience nausea 
not directly related to anticancer treatment.1 
This has a significant impact on quality of 
life (QoL), general activity and emotional 
well-being.2 The focus of research in patients 
with cancer has centred on treatment-related 
emesis, for which there is good evidence of 
benefit for a number of agents.3 Nausea (and 
vomiting) unrelated to anticancer treatment 
remains an important and under-researched 
health problem, especially given the global 
burden of cancer.
Unlike chemotherapy-induced or radia-
tion-induced nausea and vomiting (N/V), the 
evidence base for the treatment of cancer-re-
lated N/V is sparse and weak, and most of the 
recommendations are consensus-based. The 
most recent guidelines recommend meto-
clopramide as first-line treatment, with halo-
peridol, levomepromazine or olanzapine as 
alternative options.4 The evidence to support 
the use of other antiemetics commonly used 
in advanced cancer (eg, prochlorperazine, 
promethazine and cyclizine) is from uncon-
trolled or cohort studies.
As a consequence of multiple systematic 
reviews that have highlighted the need for 
randomised controlled studies (RCTs) of 
antiemetics in patients with cancer with 
nausea not related to treatment,4–6 our group 
has undertaken a series of RCTs in an attempt 
strength and limitations of this study
 ► This is one of very few quality multisite randomised 
controlled trials (RCTs) assessing the management 
of nausea and vomiting (N/V) in patients receiving 
palliative care.
 ► No other high-quality RCT of methotrimeprazine has 
been published to date.
 ► The study builds on previous work conducted by this 
group.
 ► It assesses only the short-term control of N/V.
 ► Haloperidol is not accepted as a standard antiemetic 
in many countries.
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to redress this knowledge deficit. In an initial study, we 
compared a mechanistic approach to nausea treatment 
(whereby the choice of a specific antiemetic drug was 
based on the aetiology of the nausea and knowledge of 
emetogenic pathways and receptors) with an empirical 
approach using a single agent,7 irrespective of the under-
lying cause of nausea. Haloperidol was used as the single 
agent comparator as metoclopramide was used frequently 
in the mechanistic arm. A high response rate (over 60%) 
was achieved in the per protocol analysis, with a more rapid 
response in the aetiology-based arm but no difference in 
the primary outcome measure at 72 hours between arms. 
The study demonstrated how currently available licensed 
drugs can lead to good nausea control if given regularly, 
at an appropriate dose by an appropriate route. The 
response rate for haloperidol, supported those found in 
our previous uncontrolled study8 and justified the use of 
haloperidol as our standard antiemetic for subsequent 
studies.
Haloperidol is a butyrophenone that exerts an anti-
emetic effect by blocking dopamine receptors in the 
chemoreceptor trigger zone of the brain.9 It is commonly 
used for the treatment of N/V in patients with cancer 
and several consensus-based guidelines endorse its 
use in the palliative care setting.4 10 Despite this, there 
remains resistance to the use of this drug outside the 
specialty, often because of concern regarding poten-
tial side effects, most frequently extrapyramidal move-
ment disorders. A Cochrane review updated in 2015 
concluded that there was incomplete evidence to deter-
mine the effectiveness of haloperidol for the control of 
N/V in palliative care.5
Another agent that has been used for the management 
of refractory nausea in the palliative care setting is a broad 
spectrum phenothiazine that acts at multiple receptor 
sites to cover a number of possible causes of nausea. 
Levomepromazine is the injectable form of this medica-
tion. The oral formulation is methotrimeprazine. There 
is consensus that phenothiazines including levomeprom-
azine are likely to be beneficial in controlling N/V in 
patients with cancer, but despite wide use of this drug by 
clinicians, especially in the UK and Europe, there was a 
lack of evidence to support its effectiveness in palliative 
care patients. Uncontrolled trials have reported benefits 
in chemotherapy-induced and postoperative N/V.11 12 
Two open label studies in patients with cancer receiving 
palliative care reported high rates of N/V control.13 14 
For many years, it has been recognised that at higher 
doses, the sedative effects of this drug can be used to 
advantage in the management of terminal restlessness 
and agitation.15 A Cochrane review of levomeproma-
zine updated in 2015 failed to identify any RCTs.6 The 
common off-label use of this drug led to the develop-
ment of the current study. The null hypothesis was that 




This double-blind, RCT was undertaken in 11 sites within 
the Australian national Palliative Care Clinical Studies 
Collaborative. The study is reported in accordance with 
CONSORT guidance for RCTs. This study was part of a 
programme of work focused on the relief of nausea in 
cancer patients. 7
Patients and public involvement
The experience of participants in the first study of this 
series7 contributed to the design of the subsequent 
studies.
Participants
Participants were known to a palliative care team, were 
>18 years, had a diagnosis of cancer and nausea with 
an average score over the past 24 hours of ≥3 on an 11 
point (0–10) numerical rating scale (NRS). They had to 
be able to tolerate oral medications and comply with all 
trial requirements. Patients were ineligible if they had 
nausea related to the treatment of cancer (ie, surgery, 
chemotherapy) within 5 days of anticancer therapy, had 
nausea for which a specific antiemetic was indicated and 
randomisation to study medications alone would not be 
appropriate (such as dexamethasone for acutely raised 
intra-cranial pressure and 5HT3 antagonists for chemo-
therapy-induced or radiotherapy-induced N/V), were to 
undergo a procedure or intervention with the potential 
to affect nausea during the 3-day study period (such as 
radiotherapy to a site likely to cause nausea), had received 
methotrimeprazine or haloperidol at study doses within 
the previous 48 hours, a change in glucocorticoid dose 
within 48 hours, or poor performance status.
Consent, randomisation and masking
Potentially eligible patients were given a patient infor-
mation sheet as a basis for discussion and given time to 
consider and formulate questions. The consent form was 
signed by the participant and investigator in accordance 
with Good Clinical Practice requirements. Randomisa-
tion schedules were computer generated for each site at 
an independent central registry. There was no stratifica-
tion. Schedules for each site were allocated in a 1:1 ratio 
in randomly allocated blocks of 2 and 4 and sent to each 
site pharmacy. Both study drugs were encapsulated and 
packed with an inert substance. All capsules were opaque 
and looked identical to preserve the blinding irrespective 
of the contents. Treatment allocation was not disclosed to 
study staff, treating clinicians or investigators until data 
cleaning was complete.
treatments
Participants allocated to haloperidol received 1·5 mg 
and those allocated to methotrimeprazine 6·25 mg, both 
administered orally one time per day. Following daily 
review, the dose could be increased to 3 mg (H) and 
12·5 mg (M)/24 hours in those patients with uncontrolled 
nausea. Oral metoclopramide 10 mg (or domperidone 
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for those intolerant of metoclopramide) was charted as 
a rescue antiemetic to be given four hourly as required 
(prn).
Outcome measures
Assessments of nausea severity and distress were under-
taken daily using a NRS (0, ‘no nausea’ to 10, ‘worst 
possible nausea’).
Response was defined as at least a two-point reduction 
in average nausea score from baseline over the preceding 
24 hours, measured at 72 hours on an 11-point NRS. 
Complete response was defined as at least a two-point 
reduction in average nausea score from baseline over the 
preceding 24 hours with a final score <3/10.
The primary outcome measure was a response to 
treatment at 72 hours (end day 3). Secondary outcomes 
included the following: average, best and worst nausea 
scores, nausea distress, rescue doses delivered, episodes 
of vomiting, need to increase dose, global impression 
of change (GIC)16 and adverse events. Other measures 
were as follows: performance status,17 symptom burden,18 
QoL,19 comorbidities,20 toxicity21 and extrapyramidal side 
effects.22
statistical analysis
The superiority of methotrimeprazine compared with 
haloperidol was tested by comparing the response to each 
drug after 72 hours, relative to baseline, using a χ2 anal-
ysis of differences in response rates between treatments. 
Allowing 20% for attrition, and with estimated response 
rates of 85% for methotrimeprazine compared with 60% 
for haloperidol, it was anticipated that 126 participants 
(63 per treatment arm) should be randomised to achieve 
a sample size of 50 participants per arm, assuming 80% 
power, a simple random sampling scheme and a Type 1 
error of 5% (two-tailed). An expert group of consultant 
colleagues confirmed our premise that any new unli-
censed antiemetic should be at least 25% better than stan-
dard antiemetics to justify its use. No allowance was made 
for a design effect, assuming differences between clusters 
would be minimal.
Descriptive statistics and frequency distributions were 
generated from the patients’ demographic and clinical 
characteristics. The primary endpoint of difference in 
response to treatment at 72 hours was assessed on an 
intention-to-treat (ITT) basis whereby eligible patients 
who withdrew after commencement were classified as 
non-responders. In a secondary ITT analysis, logistic 
regression was conducted to fit the binary outcome of 
response to treatment (yes/no) at 72 hours, adjusted for 
centre, although based on data from our previous study, 
we anticipated that the associated centre effect would 
be negligible. As almost half the participants came from 
one centre, ‘centre’ was dichotomised as ‘large/others’. 
Adjustment was also made for place of care (whether 
treated in a hospital general ward, palliative care unit 
or at home/an aged care facility) and any covariates 
where an imbalance between groups was observed. 
Other secondary analyses were conducted of participants 
administered treatment as randomised (per protocol) for 
response to treatment, number of vomiting episodes and 
GIC (worse, no change, better), using χ2 tests at each 
time point. Using all available data in longitudinal anal-
yses, change in nausea scores were analysed using mixed 
effects models and generalised linear models assessed 
change in GIC (dichotomised as improved/no change or 
worse) over time. All analyses were conducted using SPSS 
V.21 (Armonk, NY, USA: IBM Corp). There was no impu-
tation for missing data.
role of the funding source
The study funder had no role in the study design, collec-
tion, analysis and interpretation of data, the writing of 
the report or the decision to submit for publication. PY 
had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
results
Of the 132 potential participants assessed for eligibility, 
121 patients were randomised between March 2015 and 
February 2017. Five patients were subsequently proven 
to be ineligible, three for protocol violations determined 
by an independent review committee and were removed 
from the analysis. The ITT sample comprised 59 patients 
assigned to haloperidol treatment and 57 to methotrime-
prazine (figure 1). At 72 hours, 52 patients had completed 
haloperidol treatment and 49 methotrimeprazine, per 
protocol, giving an attrition rate of 13%.
Randomisation achieved two groups that were similar 
with respect to baseline characteristics (table 1) except 
that participants assigned to methotrimeprazine were 
more likely to be women (70%) compared with the halo-
peridol arm (58%). The most common cancers in both 
arms were gynaecological, breast and lung. The average 
and worst nausea scores at baseline in each arm were 5·4 
and 5·3/10 and 7·6 and 7·4/10 for the haloperidol and 
methotrimeprazine arms, respectively. Nausea distress 
was reflected by a mean nausea distress score of 6·1 and 
5·9/10. Nausea was considered to be multi-factorial in 
origin in almost 80% in both arms. A dominant cause for 
nausea (most commonly central/CTZ stimulation and 
gastric stasis) could be determined in just over 40% of 
participants.
In the primary ITT analysis, the response to treatment 
at 72 hours was 75% (44/59) in the haloperidol arm and 
63% (36/57) in the methotrimeprazine arm with no 
statistically significant difference between groups (−0·11; 
95% CI: −0·30 to 0·07; p=0·18). Complete response rates 
were 56% (H) and 51% (M). In the per protocol analysis, 
there was no statistical difference in response rates; (85% 
(44/52) haloperidol and 74% (36/49) for methotrime-
prazine (−0·11; 95% CI: −0·29 to 0·07; p=0·59). Complete 
per protocol response rates were 64% (H) and 59% (M) 
(table 2).
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Figure 1 Patient flow. ITT, intention to treat; PV, protocol violation; PP, per protocol.
In a logistic regression analysis of response to treatment, 
adjusted for centre, place of care and female gender, 
there was no difference between arms. Longitudinal anal-
yses of nausea scores (baseline to day 3; figure 2) showed 
reduction in all measures over time (p<0·001), but no 
differences between treatment arms. After treatment 
completion (72 hours), patients in both arms were signifi-
cantly less distressed by nausea, compared with baseline, 
with estimated mean scores of 2.0 (95% CI: 1·2 to 2·8) 
(H) and 2·2 (95% CI:1·4 to 3·0) (M).
One-third of participants had been prescribed the 
higher dose at 72 hours (29% (H), 31% (M)). Episodes of 
vomiting decreased from over 30% at baseline to less than 
15% in each arm at 72 hours. Rescue doses of metoclopr-
amide (or domperidone) were given in around 40% of 
all participants at each time point (table 3), with a trend 
towards a greater use in the methotrimeprazine arm at 
72 hours. In both arms, of those administered rescue 
medication, the majority of participants had one or two 
doses per day (85%, 85% and 74% on days 1–3) equating 
to ≤20 mg metoclopramide (or domperidone) per day.
More participants in the methotrimeprazine arm 
reported drowsiness worse at 72 hours than at baseline 
(20% vs 12%), but this difference was not significant. 
Otherwise, side effects worse than baseline were minimal, 
specifically those relating to extrapyramidal reactions 
(table 4).
At 72 hours, compared with 24 hours, the proportion of 
patients reporting improvement in GIC increased from 
72% at 24 hours to over 80% at 72 hours. A longitudinal 
analysis confirmed the increased proportion reporting 
improved GIC, but with no statistically significant differ-
ence over time or between treatment arms. Secondary 
outcomes by time are shown in a supplementary table 
(online supplementary table S1).
DIsCussIOn
Consistent with the findings of our previous studies,7 8 
we have shown a high response rate to haloperidol with 
metoclopramide rescue doses when this drug is used for 
the management of cancer-related nausea that is not asso-
ciated with anticancer treatment. This justifies the recom-
mendations in several guidelines.4 9 10 Concerns that this 
drug is associated with unacceptable side effects, specifi-
cally extrapyramidal effects, do not seem to be justified at 
least in the short term, with very few reports of this from 
both studies, as well as pharmacovigilance audits.23
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Table 1 Baseline characteristics
Characteristic
Haloperidol (n=59) Methotrimeprazine (n=57)
No. % Mean SD No. % Mean SD
Age (years)     66.2 10.2     67.9 12.0
Female gender 34 57.6     40 70.2     
Place of care             
  Inpatient palliative care 20 34.5 17 29.8
  Hospital general ward 20 33.3 18 31.6
  Private home 18 32.1 22 38.6
  Residential aged care 1 1.7 0 0.0
Primary cancer diagnosis       
  Breast 9 15.3     9 15.8     
  Lung 7 11.9     12 21.1     
  Colorectal 3 5.1     3 5.3     
  Gynaecologic 9 15.3     9 15.8     
  Gastrointestinal 3 5.1     6 10.6     
  Pancreas 6 10.2     3 5.3     
  Prostate 7 11.9     3 5.3     
  Other 15 25.4     12 21.1     
Performance status* (0–100)             
  Median (IQR) 50 (30–90) 50 (30–90)
Quality of life† (1–7)   3.3 1.6   3.1 1.4
Symptom burden‡ (0–90)     42.8 16.4     41.2 15.5
Charlson Comorbidity Index     6.6 1.8     6.5 2.0
Vomited in last 24 hours (Yes) 26 44.1     19 33.3     
Number of vomiting episodes       
  Median (range) 0   (0–12) 0 (0–5)
Antiemetics post-screening (Y) 24 40.7 23 40.4
Duration of current nausea
  <1 week 6 10.2 4 7.0
  1 up to 2 weeks 11 18.6 9 15.8
  2 up to 4 weeks 13 22.0 14 24.6
  1 up to 2 months 6 10.2 11 19.3
  ≥2 months 23 39.0 19 33.3
Nausea score (0–10)                 
  Worst 7.6 2.1 7.4 1.8
  Best 2.9 2.5 2.7 2.3
  Average 5.4 1.7 5.3 1.3
  Distress 6.1 2.9 5.9 2.7
Nausea interference§ (0–100)     51.7 25.2     49.4 18.6
Nausea—multi-factorial 47 79.7     45 78.9     
Dominant cause of nausea                 
  Undetermined 34 57.6     31 54.4     
  Central/CTZ stimulation 12 20.3     15 26.3     
  Gastric stasis 6 10.2     8 14.0     
  Other 7 11.9     3 5.3     
No. adverse events¶ (0–11)     4.8 2.6     5.1 1.9
Adverse event prior to study drug¶               
  Fatigue 47 79.7     53 93.0     
Continued
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Characteristic
Haloperidol (n=59) Methotrimeprazine (n=57)
No. % Mean SD No. % Mean SD
  Dry mouth 39 66.1     41 71.9     
  Drowsiness 35 59.3     34 59.7     
  Constipation 29 49.2     27 47.4     
  Dyspepsia 20 33.9     18 31.6     
  Bruising 20 33.9     15 26.3     
  Dizziness 19 32.2     16 28.1     
  Bowel colic 14 23.7     16 28.1     
  Blurred vision 12 20.3     10 17.5     
  Headache 10 17.0     13 22.8     
  Hypertension 5 8.5     9 15.8     
  Diarrhoea 7 11.9     7 12.3     
  Sensitivity to light 3 5.1     6 10.5     
  Voiding difficulty 5 8.5     5 8.8     
  Hypotension 5 8.5     4 7.0     
  Confusion 4 6.8     5 8.8     
  Jaundice 3 5.1     3 5.3     
  Extrapyramidal reactions 2 3.4     1 1.8     
  Palpitations 1 1.7     4 7.0     
  Allergic skin reaction 1 1.7     1 1.8     
*Australian-modified Karnofsky performance status scale.
†EORTC-QLQ-C15-PAL.
‡Edmonton Symptom Assessment Scale.
§Nausea Interference Scale.
¶Any grade.
CTZ, chemoreceptor trigger zone.
Table 1 Continued
Table 2 Primary and secondary response outcomes
Type of response (Yes) at 
72 hours
Haloperidol Methotrimeprazine Total
P value*n n (%) n n (%) n n (%)
Intention-to-treat analysis
  Response† 59 44 (74.6) 57 36 (63.2) 116 80 (69.0) 0.18
  Complete response‡ 59 33 (55.9) 57 29 (50.9) 116 62 (53.4) 0.59
Per protocol analysis
  Response 52 44 (84.6) 49 36 (73.5) 101 80 (79.2) 0.17
  Complete response 52 33 (63.5) 49 29 (59.2) 101 62 (61.4) 0.66
*χ2 test of differences between treatment groups.
†≥2-point difference from baseline.
‡ 2-point difference from baseline and end score <3
Contrary to expectations, we found no difference in 
response rate between methotrimeprazine and haloper-
idol in this setting. Methotrimeprazine is used widely in 
those countries in which it is readily available (eg, the 
UK) and often by clinicians in other countries with prior 
experience in its use. It is anecdotally considered by 
many to be superior to many other agents and is there-
fore used in refractory nausea when other agents have 
failed to result in adequate control. The sedative effects 
of this drug at higher doses can be used to advantage for 
terminal sedation; thus, it is not infrequently used for 
this indication in dying patients. At the doses used in this 
study, there appeared to be a trend towards greater seda-
tion in the methotrimeprazine arm, but the difference 
was not statistically significant.
In our previous study,7 we demonstrated high response 
rates in cancer-related nausea using freely available, inex-
pensive antiemetics when given regularly at adequate 
dose. Subsequently, we have shown that methotrimepra-
zine is not superior to haloperidol. In fact, our series of 
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Figure 2 Nausea scores over time. MTZ, methotrimeprazine.









N n (%) N n (%) n (%)
24 hours 1 13 (50.0) 17 (60.7) 30 (55.6)
2 10 (38.5) 6 (21.4) 16 (29.6)
3 2 (7.7) 5 (17.9) 7 (13.0)
4 1 (3.8) 0 (0.0) 1 (1.9)
Total 57 26 (45.6) 57 28 (49.1) 114 54 (47.4)
48 hours 1 10 (55.6) 16 (72.7) 26 (65.0)
2 5 (27.8) 3 (13.6) 8 (20.0)
3 2 (11.1) 3 (13.6) 5 (12.5)
4 1 (1.9) 0 (0.0) 1 (1.0)
Total 55 18 (32.7) 53 22 (41.5) 108 40 (37.0)
72 hours 1 10 (62.5) 13 (65.0) 23 (63.9)
2 1 (6.3) 3 (15.0) 4 (11.1)
3 4 (25.0) 3 (15.0) 7 (19.4)
4 1 (6.3) 1 (5.0) 2 (5.6)
Total 52 16 (30.8) 49 20 (40.8) 101 36 (35.6)
antiemetic studies has failed to show that any drug is supe-
rior to regular, low-dose haloperidol in this setting. This 
suggests that the newer, and often more expensive agents 
unlicensed for this indication (such as ondansetron, olan-
zapine as well as methotrimeprazine) should only be used 
second line and preferably within a monitored or trial 
context in the palliative care setting until further data are 
available.
The majority of participants in this study had nausea that 
was not associated with vomiting, illustrating once more that 
there is a need to consider nausea and vomiting separately.2 
Moreover, nausea is more frequently being considered in 
studies of chemotherapy-induced N/V where historically, 
control of emesis has always been the primary outcome 
measure.24
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Table 4 Adverse events
Adverse event*
Haloperidol (n=52) Methotrimeprazine (n=49)
Number %† Number %†
Drowsiness 6 11.5 10 20.4
Fatigue 9 17.3 8 16.3
Constipation 7 13.5 6 12.2
Headache 6 11.5 4 8.2
Dry mouth 4 7.7 4 8.2
Hypotension 2 3.9 4 8.2
Dyspepsia 3 5.8 3 6.1
Hypertension 3 5.8 3 6.1
Diarrhoea 3 5.8 3 6.1
Bruising 1 1.9 3 6.1
Dizziness 3 5.8 2 4.1
Bowel colic 1 1.9 2 4.1
Blurred vision 0 0.0 2 4.1
Confusion 1 1.9 1 2.0
Sensitivity to 
light
0 0.0 1 2.0
Palpitations 0 0.0 1 2.0
Jaundice 0 0.0 1 2.0
Extrapyramidal 
reactions
1 1.9 0 0.0
Voiding 
difficulty
1 1.9 0 0.0
Total events 29 31
*Any grade, worse at 72 hours than at baseline.
†% based on number of patients.
Limitations of this study include the use of breakthrough 
metoclopramide (or domperidone), although the dose 
per participant was ≤20 mg in the majority of participants 
with no difference between arms. Similarly, haloperidol is 
not considered as a standard antiemetic in some countries 
and the dose used may be considered higher than neces-
sary, especially in elderly patients. Further work is needed 
to establish appropriate dosing for this indication.25 Our 
primary outcome measure was at 72 hours; we have not 
assessed the longer-term benefit of these drugs nor the 
longer-term toxicity.
One of the main strengths of this study is that it was 
a multisite effectiveness study that enrolled participants 
frequently seen in palliative care services. The relatively 
rapid rate of recruitment confirms its acceptability to 
patients, their families and staff. The outcomes measures 
reflected factors that are important to patients.
It is now difficult to justify the use of a placebo arm 
in controlled clinical trials of patients with cancer with 
nausea unrelated to chemotherapy or radiotherapy given 
the weight of evidence that has been generated from 
our series of nausea studies.7 8 Future studies should 
consider regular haloperidol as the standard compar-
ator. The optimal dose of haloperidol must be deter-
mined however, as it may be lower than that used in this 
study. Furthermore, longer-term efficacy and toxicity data 
for this and other medications used for nausea must be 
defined. We have not tested haloperidol ‘head to head’ 
with metoclopramide, but the latter drug was present in 
many of the arms in our previous guideline versus single 
agent (haloperidol) study.7
In settings where people have ongoing nausea unrelated 
to anticancer treatment, low-dose haloperidol with meto-
clopramide rescue should be considered a first-line agent. 
This is widely available even in low-income and middle-in-
come countries. Although there is a temptation to use new, 
more expensive agents in this setting, their benefit over and 
above haloperidol has yet to be established.
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